The FDA Voted A Drug For Alzheimer’s Is Showing ‘Clinical Benefit’

If Lecanemab receives full FDA approval, it will provide broader coverage, meaning patients could get greater access to the treatment.

The FDA voted unanimously in agreement that a new drug is showing ‘clinical benefit’ for the treatment of Alzheimer’s.

Lecanemab is a monoclonal antibody sold under the brand name Leqembi. It is one of the first dementia drugs that appears to slow the progression of cognitive decline.

Though there were some safety concerns with certain side-effects, the FDA approved the drug for people with mild dementia back in January.

If Lecanemab receives full FDA approval, it will provide broader coverage, meaning patients could get greater access to the treatment.

The agency is expected to deliver their official decision by July 6th.